Mostrar el registro sencillo del ítem
Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
dc.contributor.author | Triviño Ibáñez, Eva María | |
dc.contributor.author | Sánchez-Vañó, Raquel | |
dc.contributor.author | Sopena Novales, Pablo | |
dc.contributor.author | Romero Fábrega, Juan Carlos | |
dc.contributor.author | Rodríguez Fernández, Antonio | |
dc.contributor.author | Carnero Pardo, Cristóbal | |
dc.contributor.author | Martínez Lozano, María Dolores | |
dc.contributor.author | Gómez Río, Manuel | |
dc.date.accessioned | 2020-05-14T11:28:59Z | |
dc.date.available | 2020-05-14T11:28:59Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Triviño-Ibáñez, E. M., Sánchez-Vañó, R., Sopena-Novales, P., Romero-Fábrega, J. C., Rodríguez-Fernández, A., Pardo, C. C., ... & Gómez-Río, M. (2019). Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine, 98(29). | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/62085 | |
dc.description.abstract | To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive impairment that meets appropriate use criteria (AUC). A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan was considered as cognition-specific or noncognition-specific. Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution, that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive- PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid- PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started, before amyloid-PET, in 80 patients (37.9%). This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled clinical AUC. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wolters Kluwer Health, Inc | es_ES |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Alzheimer’s disease | es_ES |
dc.subject | Appropriate use criteria | es_ES |
dc.subject | Amyloid PET | es_ES |
dc.subject | Mild cognitive impairment | es_ES |
dc.subject | Florbetaben PET | es_ES |
dc.title | Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.1097/MD.0000000000016509 |